According to the head of the Australian Stock Exchange, the world should be on the lookout for another mining boom by around 2020 by providing grants to mining companies. The Herald Sun reports that Chief Executive Elmer Funke Kupper states that the Federal Government should be lighter with the burden placed upon new mining companies by giving them a grant worth at least $150 million a year; a similar one has been set in Canada and has been very successful. According to Kupper, this would allow for new companies to share losses with investors rather than waiting seven years for actual operations to begin. He also added that $220 billion in mining equity capital was raised from 2007 to 2011 and may easily grow as technology improves.
A company also seeking such grants from the Federal Government is Urban Hydroponics Inc (OTCMKTS:URHY), which was formerly known as Placer Del Mar, Ltd. The difference is, though, that rather than being in Australia, this company is set in the United States. The company started out in Nevada on May 13, 2005, in order to mine and explore for minerals. On November 5, 2014, the Company signed a Binding Letter of Intent to merge three companies based in Canada into the urban cultivation sector. The companies are Urban Cultivator Inc., BC Northern Lights Enterprises Ltd., and W3 Metal Inc. Here’s a look at that CEO, Frank Terzo, stated:
“This proposed merger transaction will bring public two of the leading name brands in hydroponics. Urban Cultivator and BC Northern Lights appliances have received accolades from trade publications and high-profile users alike. The increasing awareness around eating locally grown, higher nutrition foods that reduce our carbon footprint is a driving force behind the expanding growth of this market. We look forward to completing this merger transaction by the end of the calendar year.” Over the last few weeks, URHY has seen a lot of momentum. On October 16th, URHY hit a three-month low of $0.65 and traded with a volume of 7,500. Two weeks later, on October 30th, Urban Hydroponics Inc(OTCMKTS:URHY) grew 67.6% percent to a three-month high of $1.09. On that day, URHY and traded at twice the volume it did just two weeks before at 18,297.
Eanings Review: Rambus Inc. (NASDAQ:RMBS), Revlon Inc (NYSE:REV)
Revlon Inc(NYSE:REV) +2.5% after-hours after announcing that President and CEO Fabian Garcia is stepping down “to pursue other opportunities,” and Executive Vice Chair Paul Meister will oversee operations on an interim basis.
REV also says it expects Q4 revenues of $785M, below $801M from the year-earlier quarter but ahead of analyst consensus estimate of $743M, and a $60M-$80M net loss for the quarter due to a charge related to the recent tax law changes.
REV expects Q4 adjusted EBITDA of $110M-$115M vs. $115M analyst consensus.
CFO Chris Peterson also denies rumors that the company is considering a material asset transfer that would shield assets from lenders.
Rambus Inc.(NASDAQ:RMBS) shares are down 5.5% aftermarket following Q4 results that beat revenue estimates and met on EPS. In-line Q1 guidance (under ASC 605 accounting change) has revenue from $94M to $100M (consensus: $100.38M) and EPS from $0.17 to $0.23 (consensus: $0.18).
Revenue breakdown: Royalties, $77.9M (+10% Y/Y); Product, $8.5M (-27%); Contract and other revenue, $15.5M (+2%); Licensing billings, $76.6M (+18%).Key metrics: Non-GAAP operating margin, 31%; total operating expenses, $67.5M; cash and equivalents, $172.2M; cash flow from operations, $33.3M.
ADTRAN, Inc. (NASDAQ:ADTN) Hits New Lows After Issuing disappointing Earnings Forecast
ADTRAN, Inc.(NASDAQ:ADTN) slumped to a 52-week low after forecasting below consensus guidance for Q4, revising its revenue estimate downward to $125M from $155M-$165M earlier and seeing EPS of ~$0.01; analysts had expected EPS of ~$0.14 and revenue of $161.2M.
ADTN also projects Q1 to come in at roughly the same as Q4, misses analyst consensus of $167.5M.
CEO Tom Stanton says Q4 results have been hurt by a merger-related review, which ADTN expects to be completed in 60-90 days, and slowdown in the spending at a domestic Tier 1 customer.
MKM Partners analyst Michael Genovese believes the customer is CenturyLink (CTL -2%), which accounted for 24% of ADTN’s total sales in 2016.
The analyst thinks the weakness should prove temporary, adding that ADTN’s performance likely will accelerate into 2019 as the company stands to benefit from 5G spending; MKM trims its ADTN target price to $25 from $27 but keeps its Buy rating.
Big IPO Coming: Celator Pharmaceuticals Inc(NASDAQ:CPXX), Moleculin Biotech’s (MBRX)
Today at 10am Eastern, Moleculin Biotech ticker symbol MBRX will debut on the Nasdaq stock exchange and is being considered as one of the most highly anticipated IPO’s of 2016 by the street. The excitement and anticipation is arising from many experts saying that Moleculin Biotech’s (MBRX) drug annamycin is far superior to Celator Pharmaceuticals Inc(NASDAQ:CPXX) drug daunorubicin.
CPXX which has been bought out by Jazz Pharmaceuticals plc – Ordinary Shares(NASDAQ:JAZZ) for $1.5 Billion Dollars last week, share price ran from $1.6 to $31 in 2 months. Moleculin Biotech’s share structure is a 1.5m public float Priced at $6.